Evidence map›Paper›PMID 40051684›Full record

ArticlePsychedelic medicine (New Rochelle, N.Y.)2024

Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.

Crystal Lederhos Smith, Nathan Sackett, Brian Connor Stark, Victoria Dinh, Ellen Wager Romesburg, John Roll

Abstract read
In one paragraph

Article in Psychedelic medicine (New Rochelle, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Crystal Lederhos SmithElson S. Floyd College of Medicine, Laboratory for Innovations in Therapeutics, Analytics and PsychoPharmacology Laboratory, Washington State University, Spokane, Washington, USA.ORCID https://orcid.org/0000-0002-5095-2822
Nathan SackettDepartment of Psychiatry and Beha vioral Sciences, Center for Novel Therapeutics in Addiction Psychiatry, University of Washington, Seattle, Washington, USA.
Brian Connor StarkElson S. Floyd College of Medicine, Laboratory for Innovations in Therapeutics, Analytics and PsychoPharmacology Laboratory, Washington State University, Spokane, Washington, USA.
Victoria DinhElson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA.
Ellen Wager RomesburgCollege of Nursing, Analytics and PsychoPharmacology Laboratory, Washington State University, Spokane, Washington, USA.
John RollElson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, put in place in 1970. Despite the regulatory difficulty, research has rapidly expanded in the past decade. Multiple states and cities have drafted their own policies regarding the use of psychedelics. Assuming interest in psychedelics continues to expand; every opportunity should be explored to better understand how psychedelics may be helping or harming people. Objective: This study examined underground psychedelic-assisted psychotherapy providers' protocols and perspectives, to better inform policy and public health, as psychedelics increasingly are used in the United States. Methods: Transcripts of interviews were examined through qualitative content analysis. Results: The following four themes were identified: (1) personal experiences and self-healing motivated sharing and promotion of the positive effects of psychedelics as an expression of altruism, (2) guides articulated consistent, yet flexible processes, (3) guides believed that the client benefit was actualized through their own intrinsic ability to heal themselves, and (4) guides expressed an overwhelming sense of dissonance regarding psychedelic legalization, not only desiring increased access and decreased risk but also expressing concern about potential negative impacts on provider flexibility, and depersonalization that could come with standardizing this field of practice. Conclusion: In order for current research and policy to be best informed, information must be gathered from both clinical trials and observational studies of current practice. This study identified themes within the latter to provide perspectives, practices, and insights of current underground practice, so it can be used to inform research and policy moving forward.

Indexed as

empathogenLSDMDMApsilocybinpsychedelic facilitators

Identifiers

PMID40051684
PMCPMC11658670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.